Novo Nordisk’s semaglutide weight-loss (Wegovy) and diabetes (Ozempic) drugs are no longer in short supply, U.S. regulators said Feb. 21, 2025, a decision that’s expected to curtail widespread access to cheaper copies of the popular medications.
Steve Christo/Corbis/Getty Images
Credit: Source link
